Ask about this productRelated genes to: ZRSR2 Blocking Peptide
- Gene:
- ZRSR2 NIH gene
- Name:
- zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2
- Previous symbol:
- U2AF1L2
- Synonyms:
- U2AF1-RS2, URP, ZC3H22
- Chromosome:
- Xp22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-24
- Date modifiied:
- 2019-04-23
Related products to: ZRSR2 Blocking Peptide
Related articles to: ZRSR2 Blocking Peptide
- The loss of chromosome Y (LOY) in leukocytes is the most prevalent form of clonal mosaicism observed in older men. Previous studies provided multiple pieces of evidence for the effect of LOY on the immune system and connected LOY to elevated risk of all major causes of mortality, including cardiovascular diseases and cancer. Despite these associations, the dynamic effects of LOY across the developmental trajectories of immune cell populations remain unclear. We utilized single-cell RNA-sequencing data from the peripheral blood mononuclear cells of 416 male donors (median age = 68) from the OneK1K cohort. LOY was identified in 45,304 cells (8.76%) and exhibited cell type-specific effects on immune cells along the differentiation trajectories. The largest frequency was detected in monocytes (18.6% in classical and 17.1% in nonclassical) with a progressive decrease along the transition trajectory from 22.6% to 15.8% (p = 2.00 × 10), and a gradual reduction in the expression of nonclassical markers LYPD2 and C1QA. LOY is associated with a profibrotic signature in classical monocytes marked by downregulation of IL1B (log FC = -0.22, p = 2.84 × 10) and MYC-regulated genes (log FC = -0.25, p = 2.22 × 10), consistent with previous observations that LOY-associated macrophages are polarized toward a fibrotic rather than inflammatory phenotype in cardiac and pulmonary injury. Notably, we detected aberrant expression of XIST, the essential X-chromosome-inactivation lncRNA that is not normally expressed in males, and upregulation of genes known to escape X-inactivation, including male-biased cancer-related genes KDM6A, DDX3X, KDM5C, and ZRSR2. Our results indicate associations between LOY and cell type-specific transcriptional changes, including aberrant X-inactivation features. - Source: PubMed
Dawoud AhmedGreen LukeRackham Owen - The 2022 European Leukemia Net (ELN) risk stratification categorizes acute myeloid leukemia (AML) with myelodysplasia-related gene (MRG) mutations - including , , , , , , , and/or - as "adverse-risk". However, the prognostic relevance of MRG mutations in patients with favorable-risk AML remains uncertain. - Source: PubMed
Publication date: 2026/03/09
Zhang LuluYing ShuangweiFang FangLi QianAn FurunLi JingwenSun JieZheng WeiyanZhai ZhiminZhu Yuanyuan - NPM1-mutated (NPM1mut) acute myeloid leukemia (AML) is generally classified as favorable-risk under the 2022 European LeukemiaNet (ELN-2022) guidelines, except in the presence of FLT3-internal tandem duplication or adverse-risk cytogenetics. However, the prognostic significance of co-occurring myelodysplasia-related gene (MRG) mutations remains unclear, with prior studies yielding inconsistent results. To clarify this issue, we conducted a systematic review and meta-analysis in accordance with PRISMA guidelines, searching PubMed, Embase, and MEDLINE through March 2025. MRG mutations were defined as pathogenic variants in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 and RUNX1, and the primary analysis incorporated studies regardless of RUNX1 inclusion. Data from ten cohorts across nine studies (one of which included an independent validation cohort), encompassing a total of 4,363 patients, were analyzed. Of these, 655 patients (15.0%) harbored co-occurring MRG mutations. Among the patients with ELN-2022 intermediate risk (n=1,294), 108 (8.3%) had MRG mutations. The presence of MRG mutations was significantly associated with inferior overall survival (pooled hazard ratio [HR] 1.30; 95% confidence interval [CI], 1.11-1.51; p. - Source: PubMed
Publication date: 2026/02/26
Chang Yu-SungLee Yi-WeiLiu Chieh-YuOthman JadEckardt Jan-NiklasZhou QianghuaTien Feng-MingLyu Ting-WeiTsai Xavier Cheng-HongLin Chien-ChinChang HongKo Bor-ShengChou Wen-ChienRöllig ChristophRussell NigelDillon RichardHou Hsin-An - Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis and potential progression to a blast phase. This review provides a comprehensive overview of the current molecular landscape of MF beyond canonical driver mutations (JAK2, MPL or CALR), emphasizing insights gained from murine models that served as valuable tools for understanding disease mechanisms. - Source: PubMed
Publication date: 2026/02/10
Boldrini ValentinaGuglielmelli PaolaVannucchi Alessandro M - The inclusion of nine myelodysplasia-related gene (MRG) mutations (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2) as adverse risk factors in the ELN risk classification has reshaped classification in acute myeloid leukemia (AML). AML with FLT3-ITD mutations and co-occurring MRG alterations is now classified to the ELN adverse risk group although supporting evidence remains limited. Among 4,078 patients with AML with available molecular information included in the HARMONY platform, 862 harbored FLT3-ITD mutations and underwent intensive chemotherapy. Of these, 171 (20%) exhibited co-occurring MRG mutations at diagnosis. In this cohort, MRGs were not independently associated with relapse-free survival (RFS) or overall survival (OS). In the FLT3-ITD/NPM1 co-mutated subgroup, MRG mutations were rare (9%) and showed no prognostic impact. Conversely, in FLT3-ITD/NPM1 wildtype AML, MRG mutations were predictive of shorter RFS (HR 1.37, 95%CI 1.01 - 1.88, p = 0.046) and OS (HR 1.34, 95%CI 1.02-1.74, p = 0.032) in multivariable analysis with survival times comparable to the ELN adverse risk category. The allelic ratio of FLT3-ITD did not further stratify OS and RFS in this subgroup. These findings suggest that the prognostic relevance of MRG mutations in FLT3-ITD AML is modulated by NPM1 co-mutational status and mirror findings in AML lacking FLT3-ITD. - Source: PubMed
Publication date: 2026/02/09
Mecklenbrauck RabeaVillaverde Ramiro AngelaSträng EricGabdoulline RazifMartinez Elicegui JavierSobas MartaPleyer LisaTurki AminVoso Maria TeresaBenner AxelHernández-Sánchez AlbertoTettero Jesse MTur Gimenez LauraMetzeler Klaus HOñate GuadalupeLehmann SörenHuntly Brian JpThomas IanThol Felicitas RHeidel Florian HValk Peter JmDöhner KonstanzeHaferlach TorstenMills Kenneth IDöhner HartmutCastellani GastoneOssenkoppele Gert JHernández-Rivas Jesus MaríaBullinger LarsHeuser Michael